Physician profile
Sonali Bora
NPI 1831375682
$6,263.17
in general payments reported to CMS, 2019-2025
22 companies · $2,287 in 2025
The $2,287 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2021: $654 · 2022: $564 · 2023: $1,073 · 2024: $1,478 · 2025: $2,287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,790 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,789.53 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $857.77 | 2021-2025 | Spravato, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $688.66 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $591.76 | 2023-2025 | Caplyta |
| Tris Pharma INC | $549.03 | 2022-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Abbvie INC. | $532.54 | 2021-2025 | Vraylar |
| Corium, LLC | $474.77 | 2021-2025 | Azstarys |
| Lundbeck LLC | $438.09 | 2022-2025 | Rexulti, Brintellix |
| Takeda Pharmaceuticals U.S.A., INC. | $364.50 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $303.33 | 2021-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $285.28 | 2021-2025 | Rexulti, Abilify Mycite |
| Alkermes, INC. | $235.76 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $225.93 | 2022-2024 | Austedo Xr |
| Ironshore Pharmaceuticals INC. | $190.70 | 2021-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $135.47 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $111.58 | 2025 | Auvelity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $102.42 | 2023-2025 | Adzenys Xr-Odt |
| Vertical Pharmaceuticals, LLC | $47.87 | 2024-2025 | Relexxii |
| Neuronetics, INC. | $43.37 | 2025 | Neurostar Tms Therapy System |
| Idorsia Pharmaceuticals US INC | $30.90 | 2023-2024 | Quviviq |
| Tempus Ai, INC | $20.00 | 2024 | |
| Brainsway USA INC | $17.05 | 2024 | Brainsway Deep Tms System |
| Avion Pharmaceuticals | $16.39 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonali Bora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.